Physician profile
Sameer Soliman
NPI 1669762191
$11,569.18
in general payments reported to CMS, 2019-2025
32 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $1,776 · 2021: $2,137 · 2022: $1,899 · 2023: $1,059 · 2024: $1,743 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,130.26 | 2019-2024 | Proclaim, Eterna, Ionicrf |
| Medtronic, INC. | $1,736.70 | 2021-2025 | Inceptiv, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $929.42 | 2019-2025 | Ajovy |
| Boston Scientific Corporation | $709.93 | 2019-2025 | General - Pain Management, Intracept |
| Relievant Medsystems, INC. | $696.87 | 2020-2023 | Intracept |
| Abbvie INC. | $602.62 | 2021-2024 | Ubrelvy, Qulipta |
| Assertio Therapeutics, INC. | $597.98 | 2019-2020 | |
| Si-Bone, INC. | $452.83 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $430.21 | 2020-2021 | |
| Painteq LLC | $321.18 | 2023-2024 | Painteq |
| Allergan, INC. | $260.85 | 2020-2022 | |
| Pfizer INC. | $252.19 | 2019-2025 | |
| Amgen INC. | $242.47 | 2019-2022 | |
| Ibsa Pharma INC. | $186.84 | 2021-2023 | Tirosint, Licart |
| Scilex Pharmaceuticals INC. | $137.83 | 2019-2023 | Ztlido |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $128.08 | 2021 | |
| Nevro Corp. | $122.42 | 2020-2024 | Senza |
| Novartis Pharmaceuticals Corporation | $101.50 | 2020-2021 | |
| Bioventus LLC | $91.77 | 2022-2025 | Supartz Fx Sodium Hyaluronate, Xcell |
| Biohaven Pharmaceutical Holding Company LTD. | $63.46 | 2022 | |
| Collegium Pharmaceutical, INC. | $63.01 | 2023-2024 | Belbuca, Xtampza |
| Spr Therapeutics, INC | $58.50 | 2022 | |
| Fidia Pharma USA INC. | $50.62 | 2025 | Hyalgan, Hymovis, Triluron |
| Grt US Holding, INC. | $41.76 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $32.09 | 2025 | |
| Biodelivery Sciences International, INC. | $25.11 | 2020-2021 | |
| Horizon Therapeutics Plc | $23.30 | 2021 | |
| Averitas Pharma INC. | $21.01 | 2024 | Qutenza |
| Kerecis Limited | $18.29 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Lilly USA, LLC | $16.06 | 2021 | |
| Vertiflex, INC. | $12.85 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.